Clinical Trial Update: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab for recurrent head and neck cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ASP-1929
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rakuten Medical, Inc. | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED